風(fēng)濕免疫疾病是一種病因尚未完全明了的疾病，臨床表現(xiàn)多樣。臨床治療主要使用非甾體抗炎藥、糖皮質(zhì)激素和以改善病情為主合成類(lèi)抗風(fēng)濕藥物。隨著近年對(duì)發(fā)病機(jī)制的深入研究，出現(xiàn)了一系列作用于靶向細(xì)胞因子或細(xì)胞表面受體的以改善病情為主的生物藥物。藥物種類(lèi)也從小分子發(fā)展到單克隆抗體再到融合蛋白等，從而加速了抗風(fēng)濕免疫藥物更加有效安全地被用于臨床治療。分析了非甾體抗炎藥、糖皮質(zhì)激素類(lèi)藥物、以改善病情為主的抗風(fēng)濕藥的臨床使用情況，為發(fā)現(xiàn)更加低毒有效地治療風(fēng)濕免疫疾病藥物提供了途徑。

Rheumatoid immune disease is a chronic systemic inflammatory disease with unknown etiology. It is an autoimmune disease mainly characterized with pain symptoms. In clinical, nonsteroidal anti-inflammatory drugs, glucocorticoids, and synthetic disease-modifying anti-rheumatic drugs are used alone or in combination to improve inflammation and reduce pain. However, with the in-depth study of the pathogenesis and the rapid development of molecular biology in recent years, a series of biological disease- modifying anti-rheumatic drugs targeting cytokines or cell surface receptors have been developed. At the same time, the types of drugs have also developed from low-molecule-weight synthetic disease-modifying anti-rheumatic drugs to monoclonal antibodies and fusion proteins, thereby accelerating the use of anti-rheumatic immune drugs in clinical treatment more effectively and safely. This paper analyzes the clinical use of nonsteroidal anti-inflammatory drugs, glucocorticoids, and anti-rheumatic drugs, which are mainly used to improve the condition of the patients, so as to provide a way to find more effective and less toxic drugs for the treatment of rheumatic immune diseases.

R977